Congenital analbuminemia caused by a novel aberrant splicing in the albumin gene by Gianluca Caridi et al.
©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://dx.doi.org/10.11613/BM.2014.017 Biochemia Medica 2014;24(1):151–8 
  151
Abstract
Introduction: Congenital analbuminemia is a rare autosomal recessive disorder manifested by the presence of a very low amount of circulating 
serum albumin. It is an allelic heterogeneous defect, caused by variety of mutations within the albumin gene in homozygous or compound hetero-
zygous state. Herein we report the clinical and molecular characterization of a new case of congenital analbuminemia diagnosed in a female new-
born of consanguineous (first degree cousins) parents from Ankara, Turkey, who presented with a low albumin concentration (< 8 g/L) and severe 
clinical symptoms.
Materials and methods: The albumin gene of the index case was screened by single-strand conformation polymorphism, heteroduplex analysis, 
and direct DNA sequencing. The effect of the splicing mutation was evaluated by examining the cDNA obtained by reverse transcriptase - polymera-
se chain reaction (RT-PCR) from the albumin mRNA extracted from proband’s leukocytes.
Results: DNA sequencing revealed that the proband is homozygous, and both parents are heterozygous, for a novel G>A transition at position 
c.1652+1, the first base of intron 12, which inactivates the strongly conserved GT dinucleotide at the 5’ splice site consensus sequence of this intron. 
The splicing defect results in the complete skipping of the preceding exon (exon 12) and in a frame-shift within exon 13 with a premature stop codon 
after the translation of three mutant amino acid residues.
Conclusions: Our results confirm the clinical diagnosis of congenital analbuminemia in the proband and the inheritance of the trait and contribute 
to shed light on the molecular genetics of analbuminemia.
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Congenital analbuminemia (CAA) (OMIM # 103600) 
is an autosomal recessive disorder manifested by 
the presence of a very low amount of circulating 
serum albumin, in the absence of hepatic dysfunc-
tion, renal or gastrointestinal losses, and redistri-
bution into extra-vascular compartments (1,2). In 
the affected individuals albumin concentration 
may range from < 1 g/L up to 10 g/L (2). This wide 
interval is probably due to the fact that the com-
monly used assays for the quantification of the 
protein in serum (based on dye-binding tech-
niques) suffer from poor accuracy in presence of 
low levels, usually showing an overestimation of 
its real amount (3).
CAA is very rare: in spite of the fact that the trait is 
readily detected by routine plasma electrophoret-
ic analysis, only just over fifty cases have been so 
far reported world-wide and are listed in the Reg-
ister of Analbuminemia Cases (4). Its prevalence is 
estimated at less than 1 in 1 million, apparently 
without gender or ethnic predilection (2). Recent 
data, however, seem to indicate that the frequency 
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of the trait is significantly higher in restricted and 
minimally admixed population groups, such as a 
gypsy settlement in Slovakia and two Amerindian 
communities in Saskatchewan (Canada), than in 
the average population (2).
In the adult population, CAA is generally thought 
as a benign condition, since the absence of the 
major blood protein is partially compensated for 
by an increase in the synthesis of other serum pro-
teins (2,5,6). As reported in the Register of Analbu-
minemia Cases, analbuminemic individuals have 
few clinical symptoms of their condition other 
than mild edema, hypotension, fatigue and, occa-
sionally, a peculiar lower-body lipodystrophy 
(mainly in adult females), while the most common 
biochemical finding is a gross hyperlipidaemia, 
with a significant increase in the total and LDL-
cholesterol concentration, but normal concentra-
tion of HDL-cholesterol and triglycerides. Due to 
the lack of follow-up data in most cases, it is hard 
to draw conclusions about the long-term outcome, 
and the possibility that analbuminemic individuals 
may be at risk for atherosclerotic complications 
cannot be ruled out (2).
In contrast to the benign presentation of CAA af-
ter birth, the prenatal course appears less favoura-
ble. Fetal or neonatal death of siblings was fre-
quently observed in the families of analbuminemic 
subjects, suggesting that albumin has a crucial 
role in fetal development (2,5,6). A recent study 
shows that CAA is a risk factor during the perinatal 
and the childhood period (7), confirming the hy-
pothesis that the rarity of the trait may be attrib-
uted to the fact that only a few analbuminemic in-
dividuals survive past the neonatal state (8,9).
All the cases of CAA so far studied at the molecular 
level are caused by mutations in the albumin gene 
(ALB), which lies on chromosome 4, near the cen-
tromere, at position 4q11-13 (74269972..74287129) 
(10). In a continuing effort towards understanding 
the molecular basis of CAA, we report here the 
clinical findings and the mutational analysis of the 
ALB in a new case of analbuminemia diagnosed in 
a Turkish female new-born.
Materials and methods
Subjects and clinical laboratory analyses
Subjects of this study were the members of a fam-
ily, composed by consanguineous (first degree 
cousins) healthy parents from Ankara, Turkey, and 
by a female new-born (the index case). At the time 
of our study the mother was 19 years old and the 
father was 26 years old. The albumin concentra-
tion was measured also in 12 healthy relatives, 
aged between 14-60 years. Those samples could 
not be submitted to genetic analysis. The clinical 
and biochemical studies were performed at the 
Department of Pediatrics, Division of Neonatology, 
of the Ankara University School of Medicine, An-
kara, Turkey in November 2012. The mutational 
analysis was done in 2013 at the Department of 
Molecular Medicine, University of Pavia, Pavia, Italy 
and at Laboratory on Pathophysiology of Uremia, 
Istituto Giannina Gaslini IRCCS, Genova, Italy.
The procedures were in accordance with the 1975 
Helsinki Declaration. We collected blood samples 
after obtaining written informed consent from all 
participants involved in the study. Albumin con-
centration in serum was measured by a modified 
bromcresol purple-binding assay. Serum protein 
electrophoresis was performed by the fully auto-
mated capillary electrophoresis system Capillarys 
2® (Sebia, Norcross, GA, USA), designed to optimise 
and completely automate electrophoresis testing. 
The method uses an alkaline buffer (Protein 6 As-
say, Sebia) for a high voltage protein separation. 
Proteins are detected by measuring UV absorb-
ance of the peptide bonds at 214 nm at the ca-
thodic capillary end. The system automatically 
generates a profile that resembles patterns ob-
tained after conventional gel electrophoresis on 
cellulose acetate or agarose. Other analytes were 
assayed by conventional techniques using a fully 
automated Beckman Coulter, DXC 800 Autoanlyser 
(Beckman Coulter Inc., Brea, CA, United States).
Mutational analysis
Fourteen genomic fragments of the ALB gene, en-
compassing the coding exons and their intron-ex-
on junctions (10), were amplified by PCR using spe-
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cific primer pairs as described by Watkins et al. (9). 
Genomic DNA from two unrelated volunteers was 
available as a control. Heteroduplex and single 
strand conformational polymorphism analysis and 
DNA sequencing were performed as previously re-
ported (11,12).
White blood cells, separated from whole blood by 
using Ficoll solution, were used for isolation of to-
tal RNA with the RNeasy Mini Kit (Qiagen, Venlo, 
Netherlands) from the proband and from one con-
trol. 1 μg of extracted RNA was used in reverse-
transcription reactions by using 10 pmol of oligo 
(dT) primers and the Quantitec reverse transcrip-
tion enzyme (Qiagen). The first strand cDNA was 
amplified by primers specific for exon 9 (ALB_1117F: 
5’-CTT GCC AAG ACA TAT GAA ACC A-3’) and exon 
14 (ALB_1816R (5’-CAG CTT GAC TTG CAG CAA 
CA-3’). The PCR products obtained were subjected 
to direct sequencing as described above.
As NCBI reference sequences we used NG_009291.1 
for ALB, NM_000477.5 for the messenger RNA, and 
NP_000468.1 for the precursor protein (pre-
proalbumin) of 609 amino acid residues.
Results
Patient
The proband was born at 333/7 gestational week 
from the second pregnancy, which was complicat-
ed by hyperemesis gravidarum up to third trimester 
and intrauterine growth retardation (IUGR). The 
mother’s first pregnancy resulted with abortion at 
8th gestational week. The new-born was delivered 
by caesarean section due to non-reactive stress 
test on follow-up for IUGR. She was small for ges-
tational age with birth weight of 1130 g (< 3rd per-
centile) and length of 39 cm (< 10th percentile). She 
was admitted to neonatal intensive care unit for 
respiratory distress observed in delivery room in 
addition to IUGR. Clinical examination was normal 
except for respiratory insufficiency which was 
managed by nasal continuous positive airway 
pressure for only four hours. Complete blood 
count on admission revealed polycythaemia (hae-
matocrit 0.670), and partial exchange transfusion 
was performed due to concurrently hypoglycae-
mia. Albumin concentration in serum, measured 
by a modified bromcresol purple-binding assay at 
24th h of life resulted abnormally low (< 8 g/L). This 
test was repeated for three times, giving the same 
result. Automated capillary electrophoresis of se-
rum proteins confirmed the presence of a similarly 
low albumin concentration associated with a com-
pensatory increase in the non-albumin protein, es-
pecially the α2- and the β-globulin fractions (Fig-
ure 1 and Table 1). Other relevant clinical chemistry 
data of the proband are reported in Table 1. Be-
sides the above mentioned severe hypoalbumine-
mia and moderate hypoproteinemia, she exhibits 
moderate dyslipidemia, with a marked increase of 
the triglyceride concentration, whereas the con-
centration of total cholesterol, LDL-cholesterol and 
HDL-cholesterol are close to the upper limit of the 
normal range. In addition, the proband shows 
moderate hypocalcemia, related to her low albu-
min concentration (1,13). The clinical condition of 
the patient deteriorated on postnatal third day, 
and she developed pulmonary haemorrhage, up-
a
b
Figure 1. Capillary electrophoresis of serum proteins. The pro-
files were obtained via the fully automated capillary electro-
phoresis system Capillarys 2® as described in Material and meth-
ods. a) patient (on postnatal second day); b) control.
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Analyte Patient values Units Normal reference range
Albumin <8 g/L 28-44
Total protein 27 g/L 44-75
α1-globulins (relative)* 2 .2 % 2.9-4.9
α2-globulins (relative)* 22 .9 % 7.1-11.8
β-globulins (relative)* 46 .4 % 8.4-13.1
γ-globulins (relative)* 13.3 % 11.1-18.8
Apolipoprotein B-100 0.901 g/L 0.55-1.25
Apolipoprotein A-1 1.24 g/L 0.79-1.87
Total cholesterol 6 .0 mmol/L < 5.17
LDL-cholesterol 2 .66 mmol/L < 2.59
HDL-cholesterol 1 .88 mmol/L 1.03-1.55
Triglycerides 4 .47 mmol/L < 1.69
Calcium 1 .42 mmol/L 2.15-2.55
Phosphate 1.65 mmol/L 1.13- 2.49
IgG 5.89 g/L 1.88-8.76
IgA 1 .34 g/L 0.01-0.16
IgM 1 .73 g/L 0.13-0.70
Transferrin 1.25 g/L 1.11-2.69
Lactate dehydrogenase 337 U/L 37°C 125-220
The values were determined in the first days of life of the analbuminemic patient. The normal reference ranges refer to 
subjects of the same age. Patient’s biochemical values outside the normal reference range are presented in bold. The analytes 
indicated in the table were assayed in serum by routine clinical laboratory procedures.
*Serum globulin fractions were detected after automated capillary electrophoresis, which reported their relative values.
Table 1. Clinical laboratory test results of the analbuminemic patient.
per gastrointestinal system bleeding and haema-
turia. She was diagnosed as disseminated intravas-
cular coagulation related to sepsis. She received 
antibiotics (vancomycin and amikacin), and sup-
ported with multiple fresh frozen plasma while she 
was on respiratory support with surfactant and 
high frequency ventilation. Patient received albu-
min infusion as 1 g/kg, and the protein concentra-
tion increased to 17 g/L. On postnatal 6th day, she 
was extubated and her clinical condition was sta-
ble up to 24th day when she had minimal edema 
on dorsum of hands and feet. The albumin concen-
tration was again low, and she received one addi-
tional infusion for abdominal distension, which was 
thought to be related to intestinal edema.
Differential diagnosis led us to congenital neph-
rotic syndrome and congenital analbuminemia 
because of normal gastrointestinal system find-
ings and age of the patient. Renal ultrasonography 
revealed normal parenchymal echogenity with 
normal size. 24 h collected urine analysis showed 
proteinuria (15-20.5 mg/m2/h, normal value < 4 
mg/m2/h) which was never above nephrotic level 
(> 40 mg/m2/h). Proteinuria resolved on follow-up 
(2.6 mg/m2/h) in the neonatal intensive care unit, 
and was thought to be related with sepsis and 
haematuria. On the basis of the above-reported 
clinical and biochemical findings, CAA was diag-
nosed. A relatively low albumin concentration was 
detected in the mother (24 g/L), in the father (36 
g/L) and in five other members of the family (Fig-
ure 2). This suggests that all of them are hetero-
zygous carriers of a mutation, which, at the ho-
mozygous or compound heterozygous state, may 
result in CAA, since those individuals generally 
have albumin concentrations close to the lower 
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zygous for the wild-type and mutated alleles, as 
the sequencing electropherograms showed the 
presence of two superimposed peaks at nucle-
otide c.1652+1 (Figure 3b and 3c). To establish the 
consequences of the present splicing mutation, 
we attempted to amplify ALB cDNA from the 
proband and from a wild type control. Amplified 
products showed different sizes: a PCR band of 476 
bp was amplified from the proband cDNA, where-
as a 700 bp fragment was obtained from the con-
trol (data not shown). Sequencing of the patient 
PCR product allowed us to establish that the G>A 
transition at the first position of intron 12 results in 
the complete skipping of the preceding exon (Fig-
Figure 2. Family pedigree.
The analbuminemic patient is represented by a black symbol. 
The albumin levels were determined in all the members of the 
second and third generation. Grey symbols indicate individuals 
who have albumin concentrations close to the lower limit of the 
normal range (about 30-35 g/L) and are therefore suspected to 
be heterozygous for the mutation. Heterozygosity was demon-
strated for the parents of the proband.
Figure 3. Genomic DNA sequence electropherograms of the 
analbuminemic patient and her parents.
The arrow indicates the nucleotide (A) which in this family sub-
stitutes the G at position c.1652 +1, the first base of intron 12 in 
a 5’ GT consensus sequence. The patient (a) is homozygous for 
the mutation, while both parents (b and c) are heterozygous for 





Exon 12 Intron 12
limit of the normal range (about 30-35 g/L), an oth-
erwise unremarkable condition (1).
On out-patient follow-up, the patient’s physical 
examination was completely normal with a weight 
of 7890 g (3rd-10th percentile) at one year of cor-
rected age. The patient’s all biochemical evalua-
tion on six out-patient follow-up during the first 
year of life revealed albumin concentration below 
8 g/L without any sign or symptom.
Mutational analysis
To confirm the diagnosis of CAA at the molecular 
level, a mutational analysis of the ALB was carried 
out as described in Materials and methods. In this 
case the combination of heteroduplex analysis 
and single-strand conformation polymorphism 
did not allow an unambiguous localisation of the 
mutation site. Therefore all the fourteen coding 
exons and their adjacent intron regions were sub-
mitted to DNA sequence analysis, which clearly in-
dicated the presence of a single mutation in the 
region encompassing exon 12 and the intron 11 - 
exon 12 and exon 12 - intron 12 junctions, that es-
caped our electrophoretic analysis. The electroph-
erogram of the proband revealed that she is ho-
mozygous for a G>A transition at position c.1652+1, 
the first base of intron 12 in a 5’ GT consensus se-
quence (Figure 3a). Both parents were hetero-
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Figure 4. Molecular effect of the novel c.1652+1G>A mutation.
a) Schematic representation of normal and aberrant mRNA splicing in the ALB. The arrow indicates the nucleotide (the G at the first 
position of intron 12) which is mutated in the patient; b) ALB cDNA sequence from the patient showing that the G>A transition at po-
sition c.1652+1, which causes the inactivation of the strongly conserved GT dinucleotide at the 5’ splice site consensus sequence of 
intron 12, results in the splicing between exons 11 and 13 with the complete skipping of exon 12; c) Predicted amino acid sequence 
of the C-terminal region of the putative variant protein product. The subsequent frame-shift within exon 13 causes the translation 
of three mutant amino acid residues (Cys-Thr-Cys) and a premature stop codon (TGA) located at amino acid position 480. The variant 




ure 3a and 3b). The subsequent frame-shift within 
exon 13 causes the translation of three mutant 
amino acid residues (Cys-Thr-Cys) and a premature 
stop codon (TGA) located at amino acid position 
480 (Figure 3c). The putative protein product, ac-
cording to the Human Genome Variation Society 
rules, is p.Leu477Cysfs4*, indicating a frame-shift-
ing change with Cysteine 477 as the first affected 
amino acid and the new reading frame being open 
for three amino acids (Figure 3c). This extensive 
modification of the C-terminal region of ALB should 
give rise to a putative polypeptide chain of 455 
amino acid residues, with a relative molecular mass 
of 51,651 and a theoretical pI of 5.61, instead of 
66,472 and 5.67 of the normal molecule. Unfortu-
nately, because of the very young age of the pa-
tient and of her not good clinical condition, we did 
not have the possibility to perform two-dimen-
sional electrophoresis, in order to check the pres-
ence in serum of this truncated albumin molecule. 
These results show that the splicing mutation here 
described, for which we suggest the name Ankara 
after the city of origin of the family, affects pre-
mRNA maturation by inactivating the 5’ splice site 
sequence at the twelfth exon-intron boundary of 
the ALB, and represents a novel genetic defect 
causing CAA.
Discussion
Direct DNA sequencing of the ALB in the index 
case allowed the identification of a novel splicing 
defect. The subsequent aberrant splicing could be 
verified at the cDNA level. The results confirmed 
the clinical diagnosis of CAA in the proband and 
the inheritance of the trait from the two hetero-
zygous parents. The only limitation of this study 
was the impossibility of testing the presence of the 
mutation in other members of the family. Pre-term 
births, presence of miscarriages in the history of 
the affected families, and respiratory tract infec-
tions with frequent hospital admissions have been 
reported in analbuminemic new-borns, who are 
often small for their gestational age (7). All those 
signs, together with other clinical complications, 
were present in the index case. This seems to con-
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firm that albumin has a crucial role in the fetal de-
velopment and its absence is a risk factor in the 
perinatal and in childhood period (2,7-9).
The first reported cases of CAA were diagnosed in 
the adult age (4). In the following years, more at-
tention to this condition and a more detailed 
knowledge of the trait led to an earlier diagnosis, 
often in the paediatric age (4). The analbuminemic 
individuals, however, are prone to misdiagnosis or 
delayed diagnosis, because of the absence of un-
ambiguous symptoms and of the presence of a 
significant, though low, amount of albumin. The 
major pitfall is that a minute albumin amount, as 
reported in the Introduction, may have many caus-
es different from a genetic lack of the protein. For 
these reasons, the clinical diagnosis needs always 
to be confirmed by a molecular diagnosis, based 
on the identification of the causative mutation 
within the ALB. The Ankara mutation is the twenty-
second different molecular defect identified as a 
cause of the analbuminemic trait (2,11). Twenty 
among them cause CAA at the homozygous state: 
six nonsense mutations, seven mutations affecting 
splicing, five frame-shift/deletions, one frame-shift/
insertion and one mutation in the start codon (2,11). 
Compound heterozygosity for the remaining two 
molecular defects, a nonsense mutation and a 
splice site mutation with subsequent reading 
frame-shift, caused CAA in an Italian man (2,11).
The length of the truncated aberrant albumins, 
produced as a consequence of these mutations, 
would range from 31 to 532 amino acid residues, 
but, to date, no evidence could be found for the 
presence of these putative protein products in the 
serum of analbuminemic individuals (2). A possible 
explanation for their absence is that all these trun-
cated proteins will partly or completely lack do-
main III. The C-terminal end of the molecule is cru-
cial for binding to the intracellular receptor FcRn, 
which acts to recycle the protein back to the blood 
(14). Alternatively, since all the mutations associat-
ed with CAA occur at least 55 bp upstream of the 
exon13-intron13 boundary, all truncated tran-
scripts could undergo nonsense-mediated RNA 
decay with no protein produced (15).
The exon/intron junctions in the ALB conform with 
the invariant dinucleotides GT and AG consensus 
sequences present at the 5’(donor) and 3’(acceptor) 
splice sites, respectively (10,16). In humans, muta-
tions that affect pre-mRNA splicing may have a 
dramatic impact on the structure, or outcome, of 
mature transcripts, on the function of their transla-
tion products and may cause phenotypic manifes-
tations (17). The most common consequence of 
splicing mutations is skipping of one or more ex-
ons, followed by the activation of aberrant 5’ do-
nor or acceptor splice sites and retention of full in-
trons in mRNA (17). Among the eight splice-site 
mutations, five affect the GT consensus dinucle-
otide sequence at the donor intron splice site: 
Baghdad (c.79+1G>A) (18), Bartin (c.1428+2T>C) 
(19), Tripoli (c.1428+1G>T) (20), Guimarães 
(c.1289+1G>A) (21), and Ankara (present paper). Al-
though the presence of truncated albumin mole-
cules in the serum could never be evidenced in 
analbuminemic individuals, in all the four cases 
(Fondi, Bartin, Guimarães and Ankara) in which 
there was performed a search for mRNA, it could 
be isolated from white blood cells, which allowed 
for a verification of the splicing defects at the 
mRNA level (2 and present paper). Thus, these four 
splicing mutations did not cause a complete deg-
radation of the variant mRNA. As in the present 
case, in analbuminemia Bartin and Guimarães the 
mutations resulted in the skipping of the preced-
ing exon (19,21), whereas in analbuminemia Bagh-
dad and Tripoli the consequence of the mutation 
on mRNA could not be evaluated (18,20).
The Ankara mutation, as the vast majority of the 
defects which cause CAA, is so far unique, having 
been found in a single individual, or in members 
of the same family or closely related families (2). 
Only in two cases, the same mutation was found 
in two unrelated subjects (2). In contrast, the two 
bases deletion c.228_229del (analbuminemia Kay-
seri) has been ascertained in thirteen analbumine-
mic individuals of nine families belonging to geo-
graphically distant and apparently distinct ethnic 
groups (2). In addition, it is very likely the cause of 
CAA in about twenty other subjects (2,7). There-
fore, it is by far the most frequent cause of the trait 
so far identified, accounting for about 40% of the 
cases characterised at the molecular level and, 
probably, for about half of the known affected in-
dividuals world-wide (2).
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The twenty-two molecular defects known to result 
in CAA are located in nine different exons (1, 3, 4, 5, 
7, 8, 10, 11, and 12) and in five different introns (1, 6, 
10, 11, and 12). This pattern seems to suggest that 
CAA is the result of widely scattered random mu-
tations (22). However, as the number of the known 
molecular defects is increasing, the data seem to 
point out to the presence of regions in the ALB that 
are prone to mutations resulting in CAA. Two of 
them appear to be localised in the intron 6-exon 7 
and exon 11-intron 11 junctions (2, 11). Other hy-
permutable regions seem to be the sequence 
c.228 – c.230 of exon 3, the CpG sequence at posi-
tion c.412 – 413 in the codon CGA for Arg138 in 
exon 4, and the sequence c.1610 – 1615 near the 3’ 
end of exon 12 (2,11).
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